(S)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanol hydrochloride | 140408-84-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: (S)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanol hydrochloride
• 英文别名: (S)-(-)-3-hydroxymethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride；[(3S)-1,2,3,4-tetrahydroisoquinolin-3-yl]methanol;hydrochloride
• CAS: 140408-84-0
• 化学式: C₁₀H₁₃NO*ClH
• 分子量: 199.68
• InChiKey: JPCUWZKJLULNGE-PPHPATTJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.11
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (S)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanol hydrochloride 在 盐酸 、 TEA 、 1-羟基苯并三唑 、 溶剂黄146 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 31.0h， 生成 2-Amino-3-(4-hydroxy-2,6-dimethyl-phenyl)-1-(3-hydroxymethyl-3,4-dihydro-1H-isoquinolin-2-yl)-propan-1-one
  参考文献：
  名称：

  Novel C-Terminus Modifications of the Dmt-Tic Motif:  A New Class of Dipeptide Analogues Showing Altered Pharmacological Profiles Toward the Opioid Receptors

  摘要：

  The design, synthesis and pharmacological evaluation of a novel class of Dmt-Tic dipeptide analogues are described. These resulting analogues bearing different C-terminal functionalities were found to bind to the human delta receptor with high affinity. One specific class of dipeptides bearing urea/thiourea functionalities showed partial to full activation of the delta receptor. Several dipeptides also showed good binding affinities with full activation of the human kappa receptor, a novel property for those ligands.

  DOI：

  10.1021/jm015532k
• 作为产物：
  描述：

  N-叔丁氧羰基-(S)-1,2,3,4-四氢异喹啉-3-羧酸 在 N-甲基吗啉 、 盐酸 、 sodium tetrahydroborate 、 溶剂黄146 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 反应 1.41h， 生成 (S)-(1,2,3,4-tetrahydroisoquinolin-3-yl)methanol hydrochloride
  参考文献：
  名称：

  Novel C-Terminus Modifications of the Dmt-Tic Motif:  A New Class of Dipeptide Analogues Showing Altered Pharmacological Profiles Toward the Opioid Receptors

  摘要：

  The design, synthesis and pharmacological evaluation of a novel class of Dmt-Tic dipeptide analogues are described. These resulting analogues bearing different C-terminal functionalities were found to bind to the human delta receptor with high affinity. One specific class of dipeptides bearing urea/thiourea functionalities showed partial to full activation of the delta receptor. Several dipeptides also showed good binding affinities with full activation of the human kappa receptor, a novel property for those ligands.

  DOI：

  10.1021/jm015532k

文献信息

• DNA-Model-Based Design and Execution of Some Fused Benzodiazepine Hybrid Payloads for Antibody–Drug Conjugate Modality
  作者：Prasanna Sivaprakasam、Ivar McDonald、Christiana Iwuagwu、Naidu S. Chowdari、Kevin M. Peese、David R. Langley、Heng Cheng、Michael R. Luzung、Michael A. Schmidt、Bin Zheng、Yichen Tan、Patricia Cho、Souvik Rakshit、Thirumalai Lakshminarasimhan、Sivakrishna Guturi、Kishorekumar Kanagavel、Umamaheswararao Kanusu、Ankita G. Niyogi、Somprabha Sidhar、Rajappa Vaidyanathan、Martin D. Eastgate、Srikanth Kotapati、Madhura Deshpande、Chin Pan、Pina M. Cardarelli、Chunshan Xie、Chetana Rao、Patrick Holder、Ganapathy Sarma、Gregory Vite、Sanjeev Gangwar

  DOI：10.1021/acsmedchemlett.0c00578

  日期：2021.3.11

  a panel of various cancer cell lines. One of the payloads was appended with a lysosome-cleavable peptide linker and conjugated with an anti-mesothelin antibody via a site-specific conjugation method mediated by the enzyme bacterial transglutaminase (BTGase). Antibody–drug conjugate (ADC) 50 demonstrated good plasma stability and lysosomal cleavage. A single intravenous dose of ADC 50 (5 or 10 nmol/kg)

  设计并执行了一个新系列，其中四氢异喹啉稠合苯二氮卓 (TBD) 环系统与 (1-甲基-1 H-吡咯-3-基) 苯 (“MPB”) 有效负载的替代物相结合，用于与单克隆抗体偶联用于抗癌治疗。DNA 模型有助于合理识别“MPB”结合成分的修饰和引导结构-活性关系的生成。当针对一组不同的癌细胞系进行测试时，这种混合系列的有效载荷表现出出色的体外活性。其中一个有效载荷附加了一个可溶酶体切割的肽接头，并通过由酶细菌转谷氨酰胺酶 (BTGase) 介导的位点特异性结合方法与抗间皮素抗体结合。抗体-药物偶联物 (ADC)50展示了良好的血浆稳定性和溶酶体裂解。在 N87 胃癌异种移植模型中，单次静脉注射 ADC 50 （5 或 10 nmol/kg）显示出强大的疗效。
• Inhibitors of farnesyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US05932590A1

  公开（公告）日：1999-08-03

  The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

  本发明涉及抑制法尼基-蛋白转移酶（FTase）和致癌基因蛋白Ras的法尼醇化的化合物。该发明进一步涉及包含本发明化合物的化疗组合物以及用于抑制法尼基-蛋白转移酶和致癌基因蛋白Ras的法尼醇化的方法。
• EP1045844A4
  申请人：——

  公开号：EP1045844A4

  公开（公告）日：2002-08-21
• INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
  申请人：MERCK & CO., INC.

  公开号：EP1045844A1

  公开（公告）日：2000-10-25
• US5932590A
  申请人：——

  公开号：US5932590A

  公开（公告）日：1999-08-03